TIMELINE

April 3, 2017

Dr. Matsangou presents research on GSK-3B and its role in head and neck carcinoma at the AACR meeting in Washington, DC.
(poster)    (press release)

March 1, 2017

Dr. Francis J. Giles joins Actuate as Chief Medical Officer. (press release)

March 29, 2016

FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma.

December 18, 2015

Actuate receives a favorable FDA Written Response to our Pre-IND Plan for the development of 9-ING-41. The FDA laid out a very clear path on tasks necessary to complete in order to submit an IND, which sets the company up well for advancing 9-ING-41 into the clinic, and ultimately, to effectively treating patients.

December 11, 2015

Actuate completes initial financing.

November 19, 2015

Andrey Ugolkov presents his work the use of 9-ING-41 in treatment-sensitive and treatment-resistant glioblastoma at the Society of Neuro Oncology meeting. (see attachment)

October 29, 2015

Actuate Forms Scientific Advisory Board

April 20, 2015

Drs. Dubrovsky and Ugolkov present research on GSK-3B and its role in neuroblastoma and glioblastoma at the AACR meeting in April 20.
(Poster 1)
(Poster 2)

April 16, 2015

License agreements are executed with both UIC and Northwestern for the technology and know-how that serves as the foundational intellectual property for Actuate Therapeutics.

Jan 16, 2015

Company is incorporated as Apotheca Therapeutics, Inc, a Delaware C Corp, with Headquarters in Fort Worth, Texas.